Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists

Annals of the Rheumatic Diseases

Volumn 63, Issue 5, 2004, Pages 530-534

  Landewe R ^a,b   Rump, B ^b   Van Der Heijde, D ^b   Van Der Linden, S ^b  

^a Dept of Int Medicine/Rheumatology ^*  (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; CLINICAL OBSERVATION; CONTROLLED STUDY; COXITIS; DATA ANALYSIS; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ETHNIC GROUP; FEMALE; FUNCTIONAL DISEASE; GENDER; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PATIENT; PATIENT REFERRAL; PHYSICIAN; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; RHEUMATOLOGY; SCORING SYSTEM; SPINE MOBILITY;

ATTITUDE OF HEALTH PERSONNEL; COHORT STUDIES; FEMALE; HEALTH PRIORITIES; HUMANS; JUDGMENT; MALE; MIDDLE AGED; PROFESSIONAL PRACTICE; RHEUMATOLOGY; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1942532197     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.011130     Document Type: Review

References (10)

1. Linden Svan der, van Tubergen A, Hidding A. Physiotherapy in ankylosing spondylitis: what is the evidence? Clin Exp Rheumatol 2002;20:S60-4.
2. Tubergen A van, Landewé R, van der Heijde D, Hidding A, Wolter N, Asscher M, et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001;45:430-8.
3. van Tubergen AM, Landewe R, van der Linden S. Spondylarthropathies: options for combination therapy. Springer Semin Immunopathol 2001;23:147-63.
4. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
5. Gorman JD, Sack KE, Davis JD. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
6. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, der Vlam K, Mielants H, et al. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol 1999;26:961-5.
7. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, der Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-4.
8. van der Heijde D, Calin A, Dougados M, Khan MA, von der Linden S, Bellamy N, et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951-4.
9. van der Heijde D, Braun J, McGonagle D, Siegel J, et al. Treatment trials in ankylosing spondylitis: current and future considerations. Ann Rheum Dis 2002;61:iii24-32.
10. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewé R, Dougados M, Mielants H, et al. Is the BASDAI an appropriate instrument to measure disease activity in ankylosing spondylitis patients with and without peripheral arthritis? Arthritis Rheum (in press).